Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 168.04
ABAX's Cash to Debt is ranked higher than
73% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.63 vs. ABAX: 168.04 )
ABAX' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: 168.04

Equity to Asset 0.89
ABAX's Equity to Asset is ranked higher than
93% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.68 vs. ABAX: 0.89 )
ABAX' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.9
Current: 0.89

0.48
0.9
F-Score: 5
Z-Score: 24.71
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.65
ABAX's Operating margin (%) is ranked higher than
95% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ABAX: 22.65 )
ABAX' s 10-Year Operating margin (%) Range
Min: -930   Max: 22.65
Current: 22.65

-930
22.65
Net-margin (%) 14.76
ABAX's Net-margin (%) is ranked higher than
93% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.95 vs. ABAX: 14.76 )
ABAX' s 10-Year Net-margin (%) Range
Min: -900   Max: 51.27
Current: 14.76

-900
51.27
ROE (%) 15.58
ABAX's ROE (%) is ranked higher than
88% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ABAX: 15.58 )
ABAX' s 10-Year ROE (%) Range
Min: -86.54   Max: 44.04
Current: 15.58

-86.54
44.04
ROA (%) 13.61
ABAX's ROA (%) is ranked higher than
94% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.07 vs. ABAX: 13.61 )
ABAX' s 10-Year ROA (%) Range
Min: -74.38   Max: 38.83
Current: 13.61

-74.38
38.83
ROC (Joel Greenblatt) (%) 52.66
ABAX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.52 vs. ABAX: 52.66 )
ABAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -198.89   Max: 52.66
Current: 52.66

-198.89
52.66
Revenue Growth (%) 14.70
ABAX's Revenue Growth (%) is ranked higher than
90% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.90 vs. ABAX: 14.70 )
ABAX' s 10-Year Revenue Growth (%) Range
Min: 7.3   Max: 93.9
Current: 14.7

7.3
93.9
EBITDA Growth (%) 23.70
ABAX's EBITDA Growth (%) is ranked higher than
91% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.00 vs. ABAX: 23.70 )
ABAX' s 10-Year EBITDA Growth (%) Range
Min: -33.7   Max: 171.4
Current: 23.7

-33.7
171.4
EPS Growth (%) 28.50
ABAX's EPS Growth (%) is ranked higher than
93% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.30 vs. ABAX: 28.50 )
ABAX' s 10-Year EPS Growth (%) Range
Min: -59.2   Max: 159.6
Current: 28.5

-59.2
159.6
» ABAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ABAX Guru Trades in Q1 2013

Paul Tudor Jones 5,600 sh (New)
Chuck Royce 293,300 sh (+2.02%)
Manning & Napier Advisors, Inc Sold Out
Jim Simons 5,500 sh (-94.86%)
» More
Q2 2013

ABAX Guru Trades in Q2 2013

Steven Cohen 62,500 sh (New)
RS Investment Management 467,780 sh (New)
Chuck Royce 323,100 sh (+10.16%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
Q3 2013

ABAX Guru Trades in Q3 2013

Jim Simons 37,971 sh (New)
Steven Cohen Sold Out
RS Investment Management Sold Out
Chuck Royce 300 sh (-99.91%)
» More
Q4 2013

ABAX Guru Trades in Q4 2013

Joel Greenblatt 25,721 sh (New)
PRIMECAP Management 575,000 sh (New)
Jim Simons 100,869 sh (+165.65%)
Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-12-31 New Buy0.03%$32.4 - $41.25 $ 39.176%575000
Joel Greenblatt 2013-12-31 New Buy0.02%$32.4 - $41.25 $ 39.176%25721
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 51.70
ABAX's P/E(ttm) is ranked lower than
64% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.50 vs. ABAX: 51.70 )
ABAX' s 10-Year P/E(ttm) Range
Min: 10.19   Max: 148.82
Current: 51.7

10.19
148.82
P/B 4.70
ABAX's P/B is ranked lower than
57% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. ABAX: 4.70 )
ABAX' s 10-Year P/B Range
Min: 2.19   Max: 14.35
Current: 4.7

2.19
14.35
P/S 4.90
ABAX's P/S is ranked lower than
58% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.63 vs. ABAX: 4.90 )
ABAX' s 10-Year P/S Range
Min: 2.48   Max: 9.5
Current: 4.9

2.48
9.5
PFCF 35.80
ABAX's PFCF is ranked lower than
71% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.36 vs. ABAX: 35.80 )
ABAX' s 10-Year PFCF Range
Min: 21.92   Max: 101.52
Current: 35.8

21.92
101.52
EV-to-EBIT 31.30
ABAX's EV-to-EBIT is ranked lower than
65% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.08 vs. ABAX: 31.30 )
ABAX' s 10-Year EV-to-EBIT Range
Min: 10.6   Max: 118.6
Current: 31.3

10.6
118.6
PEG 3.20
ABAX's PEG is ranked higher than
52% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. ABAX: 3.20 )
ABAX' s 10-Year PEG Range
Min: 0.7   Max: 13.47
Current: 3.2

0.7
13.47
Shiller P/E 53.50
ABAX's Shiller P/E is ranked lower than
60% of the 52 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.50 vs. ABAX: 53.50 )
ABAX' s 10-Year Shiller P/E Range
Min: 21.13   Max: 317.57
Current: 53.5

21.13
317.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.30
ABAX's Price/Net Cash is ranked lower than
61% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.20 vs. ABAX: 11.30 )
ABAX' s 10-Year Price/Net Cash Range
Min: 5.92   Max: 300
Current: 11.3

5.92
300
Price/Net Current Asset Value 7.70
ABAX's Price/Net Current Asset Value is ranked higher than
63% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.40 vs. ABAX: 7.70 )
ABAX' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 775
Current: 7.7

4.17
775
Price/Tangible Book 4.70
ABAX's Price/Tangible Book is ranked higher than
56% of the 136 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ABAX: 4.70 )
ABAX' s 10-Year Price/Tangible Book Range
Min: 2.17   Max: 36.9
Current: 4.7

2.17
36.9
Price/DCF (Projected) 2.30
ABAX's Price/DCF (Projected) is ranked lower than
56% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. ABAX: 2.30 )
ABAX' s 10-Year Price/DCF (Projected) Range
Min: 1.7   Max: 180.9
Current: 2.3

1.7
180.9
Price/Median PS Value 1.00
ABAX's Price/Median PS Value is ranked higher than
70% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. ABAX: 1.00 )
ABAX' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 11.11
Current: 1

0.32
11.11
Price/Peter Lynch Fair Value 4.00
ABAX's Price/Peter Lynch Fair Value is ranked lower than
69% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. ABAX: 4.00 )
ABAX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.47   Max: 37.65
Current: 4

0.47
37.65
Price/Graham Number 3.30
ABAX's Price/Graham Number is ranked lower than
65% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ABAX: 3.30 )
ABAX' s 10-Year Price/Graham Number Range
Min: 1.42   Max: 10.96
Current: 3.3

1.42
10.96
Earnings Yield (Greenblatt) 3.20
ABAX's Earnings Yield (Greenblatt) is ranked lower than
53% of the 120 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. ABAX: 3.20 )
ABAX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 9.5
Current: 3.2

0.8
9.5
Forward Rate of Return (Yacktman) 14.39
ABAX's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.42 vs. ABAX: 14.39 )
ABAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.4   Max: 43.2
Current: 14.39

-4.4
43.2

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AXS.Germany
Abaxis, Inc. was incorporated in California in 1989. The Company develops, manufactures, markets and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements. It offers point-of-care blood chemistry analyzer, which consists of a compact portable analyzer and a series of single-use plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 14 tests on human patients and 13 tests on veterinary patients. The Company markets the blood analysis systems under the Piccolo Xpress, Piccolo Classic, VetScan VS2, and VetScan Classic names. The Company also provides VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, it offers VetScan VSpro, which assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular coagulation, hepatic disease, monitoring therapy, and the progression of disease states; VetScan VSpro fibrinogen test to provide in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT 1 that delivers blood gas, electrolyte, basic blood chemistry, and hematology results. Further, the company provides Canin Heartworm rapid test to detect dirofilaria immitis in canine whole blood, serum, or plasma; Canine Parvovirus rapid test to detect canine parvovirus antigen in feces; VetScan Giardia rapid test to detect giardiasis, a gastrointestinal infection caused by the protozoan parasite Giardia; and Canine Lyme rapid test to detect Borrelia burgdorferi in canine whole blood, serum, or plasma. Additionally, it offers veterinary reference laboratory diagnostic and consulting services. The Company sells its products through direct sales force and independent distributors.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide